Acambis
Stephen McGarry, PhD, analyst at Goldman, Sachs, leapt to the defence of Acambis, calming the nerves of those investors who may have been concerned by the recent announcement from Bavarian Nordic when they were granted a US patent covering MVA-BN, the wording of which 'could be interpreted as being negative for Acambis'. 'We do not believe this interpretation on any level is valid or warranted and should Acambis's shares weaken, we would buy the stock,' says Goldman Sachs.